[June 18, 2014]

ERYTECH appoints two new independent board members

Regulatory News:

ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent members to its board of directors.

Martine George, M.D. is a very experienced, US based clinical research, medical affairs and regulatory affairs executive, both in large and small oncology companies. Until recently Dr George was Vice President Global Medical Affairs, Oncology at Pfizer in New York. Her previous functions before Pfizer included Chief Medical Officer at GPC Biotech in Princeton and Head of oncology at Johnson & Johnson in New Jersey. Martine George is a board certified Medical Oncologist and Gynecologist, trained in France and Montréal. She started her career as a clinician as Service Chief at Institut Gustave Roussy in France and as Visiting Professor at Memorial Sloan Kettering Cancer Center in New York.

Hilde Windels has over 20 years' experience in corporate finance, capital markets and strategic initiatives. She is the Chief Financial Officer of Biocartis, a molecular diagnostics and immunodiagnostics company based in Belgium and Switzerland. Before Biocartis, Hilde was Devgen's CFO (Euronext: DEVG) from 1999 until the end of 2008 and was member of Devgen's board from 2001 until the end of 2008. From early 2009 to mid 2011, she worked as independent CFO for a few private biotechnology companies, and she sat on the board of MDX Health (Euronext: MDXH) from June 2010 until end of August 2011. Previously, she was responsible at ING for commercial banking in one of the Belgian areas. She holds a degree in Economics from the Universty of Leuven (Belgium).

"We are delighted and proud to have these seasoned professionals joining our Board of Directors. Their respective experiences in oncology drug development and financial affairs will be of great value at this important time for the company. With Phase III data for our lead product expected in a few months, and three other clinical programs ongoing, in Europe and the USA, ERYTECH making its steps to build a strategic value in orphan oncology," comments Gil Beyen, Chairman and CEO of ERYTECH.

About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com

ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors. The company is also developing other indications in solid tumors and certain orphan indications outside oncology.

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable and Next Biotech indexes. ERYTECH shares are eligible to PEA-PME (French share savings plan for SMEs).

For more information about the Company, please read About ERYTECH and ERY-ASP/GRASPA

Forward-looking information

This document may contain forward-looking statements, forecasts and estimates ("Statements") with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH Pharma. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties for which ERYTECH Pharma makes no representations or warranty as to their accuracy or fairness. Furthermore, such Statements only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such Statements except to the extent required by French law.

For more information about Forward-looking information, please read Forward-looking information

[ Back To TMCnet.com's Homepage ]